SCHEMBL6030809

SCHEMBL6030809

O=C(Nc1ccc(Cc2ccncc2)cc1)C(=O)Nc1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.58
FLT1 P17948 7/20 0.58
BLM P54132 1/20 0.55
GRM4 Q14833 1/20 0.53
PDK1 Q15118 1/20 0.52
PDGFRB P09619 1/20 0.52
KIT P10721 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
TSHR P16473 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
TRPV1 Q8NER1 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16628086 0.93 KDR (0.68) KDRFLT1BLMMEN1KMT2A
SCHEMBL5635453 0.92 KDR (0.57) KDRFLT1BLMGRM4PDK1
SCHEMBL3544690 0.86 RAF1 (0.61) KDRFLT1BLMSMN1; SMN2HPGD
SCHEMBL3551571 0.83 KDR (0.62) KDRFLT1BLMGRM4PDGFRB
SCHEMBL3551573 0.83 KDR (0.62) KDRFLT1BLMGRM4PDGFRB
SCHEMBL6030563 0.83 RAF1 (0.64) KDRFLT1PDGFRBKITMEN1
SCHEMBL16620661 0.80 KDR (0.72) KDRSMN1; SMN2NPSR1MEN1KMT2A
SCHEMBL28325011 0.79 KDR (0.69) KDRGRM4PDK1SMN1; SMN2NPSR1
SCHEMBL13300975 0.77 KDR (0.76) KDRFLT1PDGFRBKITMEN1
SCHEMBL1790420 0.77 CA1 (0.67) KDRFLT1BLMTRPV1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060189665-A1 Oxamide derivatives useful as raf-kinase inhibitors MERCK PATENT GMBH (DE) 2006-08-24 US disclosed
EP-1606260-A1 OXAMIDE DERIVATIVES USEFUL AS RAF-KINASE INHIBITORS MERCK PATENT GmbH (DE) 2005-12-21 EP disclosed
WO-2004085399-A1 OXAMIDE DERIVATIVES USEFUL AS RAF-KINASE INHIBITORS MERCK PATENT GMBH (DE) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189665-A1 Oxamide derivatives useful as raf-kinase inhibitors BRAF, RAF1, ARAF KDR 474/4885FLT1 300/4885BLM 2875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.